243 related articles for article (PubMed ID: 27853981)
1. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
[TBL] [Abstract][Full Text] [Related]
2. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
3. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
6. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
8. A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects.
Ono Y; Nishida T; Hyllested-Winge J; Seino H; Sasaki T
Diabetol Int; 2016 Dec; 7(4):404-412. PubMed ID: 30603293
[TBL] [Abstract][Full Text] [Related]
9. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
10. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
[TBL] [Abstract][Full Text] [Related]
11. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.
Heise T; Nosek L; Roepstorff C; Chenji S; Klein O; Haahr H
Diabetes Ther; 2014 Jun; 5(1):255-65. PubMed ID: 24888255
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
Güneş E; Güneş M
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
[TBL] [Abstract][Full Text] [Related]
14. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
15. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
[TBL] [Abstract][Full Text] [Related]
16. A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes.
Linjawi S; Lee BW; Tabak Ö; Lövdahl S; Werther S; Abusnana S
Diabetes Ther; 2018 Feb; 9(1):1-11. PubMed ID: 29129018
[TBL] [Abstract][Full Text] [Related]
17. Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
Onder CE; Kuşkonmaz SM; Koc G; Firat S; Omma T; Taskaldiran I; Gokbulut P; Culha C
Acta Endocrinol (Buchar); 2020; 16(4):443-448. PubMed ID: 34084235
[TBL] [Abstract][Full Text] [Related]
18. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Kumar A; Franek E; Wise J; Niemeyer M; Mersebach H; Simó R
PLoS One; 2016; 11(10):e0163350. PubMed ID: 27760129
[TBL] [Abstract][Full Text] [Related]
20. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Heise T; Tack CJ; Cuddihy R; Davidson J; Gouet D; Liebl A; Romero E; Mersebach H; Dykiel P; Jorde R
Diabetes Care; 2011 Mar; 34(3):669-74. PubMed ID: 21285389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
